Jay D. Rosenbaum’s Bristol-Myers Squibb BMY Stock Holding History

Jay D. Rosenbaum’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,721	Closed	-$494K	–	64
2023 Q2	$494K	Sell	7,721 -210	-3%	-$14.1K	0.79%	43
2023 Q1	$550K	Buy	7,931 +1,970	+33%	+$139K	1.01%	43
2022 Q4	$429K	Buy	5,961 +581	+11%	+$43.8K	0.93%	45
2022 Q3	$382K	Buy	5,380 +1,453	+37%	+$105K	0.88%	42
2022 Q2	$302K	Buy	+3,927	New	+$299K	0.58%	48

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Jay D. Rosenbaum's BMY Position: Q3 2023 in Review

Jay D. Rosenbaum sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 7,721 shares — an estimated $494K sold.

Jay D. Rosenbaum first reported a position in BMY in Q2 2022 and held it in 5 quarters. The position peaked at $550K in Q1 2023. 2,388 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

Jay D. Rosenbaum reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
Jay D. Rosenbaum sold 7,721 Bristol-Myers Squibb shares in Q3 2023, an estimated $494K.
Jay D. Rosenbaum first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 5 quarters.
Jay D. Rosenbaum's Bristol-Myers Squibb position peaked at $550K in Q1 2023.
2,388 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Jay D. Rosenbaum's 13F filing for Q3 2023, filed 23 Oct 2023.